{"id":"NCT00750737","sponsor":"M.D. Anderson Cancer Center","briefTitle":"Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)","officialTitle":"Phase III Clinical Trial of Oral Posaconazole 3 Times/Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC) for Prevention of Invasive Fungal Infections In Patients With Hematologic Malignancies & Hematopoietic Stem Cell Transplant","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-06","primaryCompletion":"2012-06","completion":"2012-06","firstPosted":"2008-09-11","resultsPosted":"2016-01-06","lastUpdate":"2016-09-29"},"enrollment":46,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Invasive Fungal Infections","Hematologic Malignancies"],"interventions":[{"type":"DRUG","name":"Posaconazole","otherNames":["SCH56592","Noxafil"]},{"type":"DRUG","name":"ABLC","otherNames":["Amphotericin B Liquid Complex","Fungizone"]}],"arms":[{"label":"Posaconazole","type":"EXPERIMENTAL"},{"label":"Amphotericin B Lipid Complex (ABLC)","type":"EXPERIMENTAL"}],"summary":"The objective of this study is to compare the safety and efficacy of ABLC versus oral Posaconazole in the prevention of invasive fungal infections in high risk patients with hematologic malignancies or hematopoietic stem cell transplant.\n\nPrimary objective is to demonstrate the low toxicity rate and low rate of invasive fungal infections associated with ABLC or Posaconazole prophylaxis.\n\nSecondary objective will be to compare the cost effectiveness of these two prophylactic regimens.","primaryOutcome":{"measure":"Incidence of Invasive Fungal Infection (IFI)","timeFrame":"Within 7 days of antifungal prophylaxis therapy","effectByArm":[{"arm":"Posaconazole 200 mg Oral","deltaMin":0,"sd":null},{"arm":"Amphotericin B Lipid Complex (ABLC) 7.5 mg/kg IV","deltaMin":5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["22814329"],"seeAlso":["http://www.mdanderson.org"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":21},"commonTop":["Nausea","Diarrhea","Increase in Creatinine","Increase in ALT","Hypomagnesemia"]}}